PHARMACEUTICS
IPO Calendar: 1 IPO, 5 listings investors need to watch out for next week
Analysts believe that despite a temporary lull, India's strong economic fundamentals and promising growth outlook create an ideal environment for its burgeoning IPO market. They foresee significant investment in public markets and robust demand for both new-age and traditional companies in the coming months.
Emcure Pharmaceuticals IPO booked nearly 68 times so far on Day 3. Check GMP and other details
Emcure Pharmaceuticals IPO sees strong demand with oversubscription. Anchor investors include top names. Company engaged in global pharmaceutical products. Revenue growth and plans for debt payment outlined. Book-running lead managers identified.
Emcure Pharmaceuticals IPO fully subscribed on Day 1. Check GMP and other details
Emcure Pharmaceuticals' IPO attracts high demand from investors, with a price range of Rs 960-1008 per share. Analysts foresee business improvements and revenue growth potential in the global pharmaceutical market, supporting the company's expansion strategies.
Emcure Pharmaceuticals IPO booked nearly 5x so far on Day 2. Check GMP and other details
Emcure Pharmaceuticals' IPO has been oversubscribed nearly three times as of Thursday, the second day of bidding. The bidding concludes on July 5. The categories reserved for NII and retail investors were subscribed the most at 13 times and 3.43 times, respectively.
Alembic Pharma gets tentative nod from USFDA for Ivosidenib tablets
The company said Ivosidenib tablets are indicated for patients with newly diagnosed Acute Myeloid Leukemia (AML) as monotherapy in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.
IPO Analysis: Emcure has better-listed pharma alternatives
Emcure Pharma, with its strong presence in gynaecology and HIV therapeutic areas, secured significant investments from anchor investors like HDFC Mutual Fund and ICICI Prudential Mutual Fund, showcasing immense market confidence in its upcoming IPO.
- Go To Page 1
Namita Thapar's Emcure Pharmaceuticals IPO opens on Wednesday. What GMP signals ahead of subscription
Emcure Pharmaceuticals' IPO opens for subscription on July 3rd with shares trading at a Rs 265 premium in the unlisted market. The IPO includes fresh equity shares worth Rs 800 crore and an Offer For Sale (OFS) of 1.14 crore shares. Priced at Rs 960-1,008 per share, investors can bid for 14 shares per lot. The company targets to raise Rs 1,952 crore at the upper price range.
Government eases rules for global sourcing of medical gear
Pavan Choudary, chairman, Medical Technology Association of India (MTAI), termed the move a path-breaking effort by the government towards equitable policy making, spanning the crucial last mile which was uncovered so far.
Kotak Equities initiates coverage on JB Chemicals with a target price of Rs 2,025
“Having primarily grown organically until FY2022 and later on aided by benefits from acquired brands, JB has handsomely outperformed the IPM in the past decade by ~600 bps and currently ranks 22 in the IPM,” said Alankar Garude, Analyst at Kotak Equities.
Emcure Pharmaceuticals IPO: 10 things to know before subscribing to the issue
Emcure Pharmaceuticals IPO is scheduled to open for subscription on July 3 and will close on July 5. The company aims to raise approximately Rs 1,952 crore through the public offer. Market analysts indicate that the current GMP of the pharma company stands at Rs 260 in the unlisted market.
It's taxing times for electoral bond buyers after Supreme Court's Feb verdict
More than 1,000 entities who purchased electoral bonds for political donations may now face inquiries from tax authorities regarding the deductions claimed on these contributions, following the Supreme Court's decision to invalidate the scheme in February. The Supreme Court, in its ruling on February 15, declared the electoral bond scheme unconstitutional. Since its introduction in January 2018, the scheme had amassed Rs 16,518 crore in donations for political parties.
IPO Calendar: Primary market gears up for another robust week as 3 companies look to raise Rs 2,700 cr
Apart from the above 3 public offers, the Street will see as many 11 listings including that of Allied Blenders and Vraj Iron and Steel, which received healthy investors' response for their IPOs in the week gone by.
India to make drugs for diabetes, obesity under PLI by 2026, says report
India plans to incentivize local manufacturing of GLP-1 drugs, crucial for treating diabetes and obesity, starting in 2026, as per a government official speaking to Reuters. These drugs, originally approved for diabetes treatment, are also used for obesity due to their ability to slow digestion and reduce appetite. Novo Nordisk's patent on semaglutide, a key ingredient in popular drugs like Wegovy and Ozempic, is set to expire in India by 2026. Indian companies are already preparing to manufacture these drugs under the government's production-linked incentive (PLI) scheme.
Risk-based audits of drug units to begin from July 1
The revised Schedule M, which is considered more stringent than the World Health Organization's (WHO) good manufacturing practices (GMP) in certain areas, was notified on December 28, 2023. Companies with turnover of over ₹250 crore will have to comply with the upgraded version of Schedule M, starting July 1, and the remaining others, which are largely micro, small, and medium enterprises (MSMEs), have been given a year's time to comply. Inspections on those firms will begin from January 1, 2025.
Indian regulator says 36% of inspected drug-making units had to be shut
India's drug regulator has ordered the closure of over 36% of its 400 drug manufacturing units since last year due to concerns over sub-standard cough syrups. The country, known as the world's pharmacy due to its large drug production, is working to restore confidence after the deaths of over 300 children worldwide linked to these syrups.
Indian Pharma exports: 'USD 10 billion opportunity up for grabs in off patent drug market by 2029'
A senior official of the Pharmexcil said drugs such as Merck's Pembrolizumab (Keytruda) whose revenue were at USD 25 billion and Bristol-Myers Squibb's Eliquis (Apixaban)-USD 12 billion, among others would be off-patented in the next few years.
Bain Capital-backed Emcure Pharma to float IPO on July 3
Emcure Pharmaceuticals, backed by Bain Capital, is set to launch its IPO on July 3. The IPO includes fresh equity shares issuance and Offer of Sale. Proceeds will be used for debt payment and corporate purposes.
Taller, stronger, sharper: Desi pharma is on a roll
The Avendus Capital report attributed the eye-catching growth of large Indian pharma brands to lifestyle diseases, prevalent quality issues that made doctors and customers rely more on big, well-known brands, along with aggressive sales and marketing push by pharma companies.
Emcure Pharmaceuticals receives SEBI nod for its IPO launch
Emcure Pharmaceuticals received SEBI nod for IPO launch after filing DRHP in December 2023. The IPO includes equity shares and an Offer of Sale by promoters. Proceeds will be used for debt payment. Emcure Pharmaceuticals is renowned for its global marketing of pharmaceutical products.
Ozempic frenzy lures rich Indians to brave the gray market
People are going to great lengths to obtain popular weight-loss drugs. They are stashing injectables in their carry-on luggage, buying counterfeit formulas online, and importing boxes from Europe. The treatments have sparked extensive media coverage, fueling a high demand. According to Goldman Sachs Research, the anti-obesity medication market could hit $100 billion by 2030. In contrast, Indians have largely been observers in this global frenzy over the new weight-loss solutions.
Expert panel to soon weigh plan to use generics for prescription drugs
An expert committee is set to discuss the feasibility of allowing generic substitutions for prescription drugs in India. The proposal has sparked a disagreement between the Indian Pharmaceutical Alliance (IPA) and the All India Drug Action Network (AIDAN). The IPA opposes the idea, arguing that it would lead to a surge of demand from trade channels, such as general pharmacy stores, which would not benefit patients.
Dr Reddy's signs in-licensing pact with Ingenus Pharmaceuticals for cancer treatment injection
Dr Reddy's Laboratories Ltd has signed a licensing agreement with US-based Ingenus Pharmaceuticals to commercialize Cyclophosphamide injection for cancer treatment. Dr Reddy's USA will commercialize the injection in the US market, paying Ingenus 50% of the calculated profit share.
Torrent Pharma signs non-exclusive patent licensing pact with Takeda Pharma for Vonoprazan
A 2019 study published by the Indian Journal of Gastroenterology revealed that the prevalence of GERD in the Indian population is around 8.2%, with a higher prevalence of around 11.1% in the urban population. According to AWACS MAT April 2024 data, the Indian market for treatments used in GERD is valued at Rs 8,064 crore, growing at 8% CAGR over the last four years.
India extends humanitarian assistance to Cuba, including 90 tonnes of nine 'Made in India' active pharmaceutical ingredients
India has provided humanitarian assistance to Cuba, including 90 tonnes of nine Made in India Active Pharmaceutical Ingredients (APIs). The aid will be used by Cuban drug manufacturers to produce essential antibiotics for treating chronic communicable diseases. The assistance reaffirms India's status as the Pharmacy of the World and underlines its commitment to the historic friendship with Cuba.
Tata Capital Healthcare Fund invests $20 million in Orbicular Pharmaceutical Technologies
The specialty generics has a market size of $60 billion and is rapidly expanding, driven by increasing demand for cost-effective alternatives to complex and high-cost branded medications. “Under the able leadership of Dr. M.S. Mohan, Orbicular has developed a strong product pipeline for the regulated markets," said Visalakshi Chandramouli, managing partner, Tata Capital Healthcare Fund.
Anti-diabetic drugs lead growth in pharmaceuticals market
The pharmaceuticals market in India is witnessing significant growth, with anti-diabetic drugs leading the way with over ₹155 crore in value growth among new brands launched in the past year. The respiratory segment and vitamin/mineral/nutrient segment followed closely behind. The anti-diabetes market has grown rapidly in the last five years, driven by factors like the increasing number of patients and the launch of new drug combinations. The pharmaceutical market rebounded in April 2024, with chronic segments showing faster growth compared to acute segments.
Load More
